Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team ...

CMiC Launches NEXUS: The First AI-Powered Construction ERP Combining Natural Language ...

NEXUS: Transforming Construction ERP into an Intelligent Business Partner CMiC NEXUS CMiC NEXUS: The First AI-Powered ...